Illumina, Inc.
Illumina, Inc. offers genetic and genomic analysis solutions globally through Core Illumina and GRAIL segments. The company provides sequencing and array-based instruments, consumables, and services including whole-genome sequencing, genotyping, and noninvasive prenatal testing. It also develops solutions for cancer diagnoses and minimal residual disease detection. Illumina serves research centers, academic institutions, hospitals, pharmaceutical companies, and consumer genomics firms. Products are marketed directly to customers and through life-science distributors.
Overview
Strengths
- Asset-light, cash-generative model: capital expenditure takes only 4.7% of revenue and free cash flow was positive in each of the last 7 years.
- ROIC of 22.9% beats 93% of its 30 Diagnostics & Research peers (median 11.3%).
- EBITDA margin of 33.8% beats 87% of its 30 Diagnostics & Research peers (median 18.7%).
- Conservative leverage: net debt is only 0.4x EBITDA.
Weaknesses
- Our discounted cash flow target price (82.15 USD) is 61% below the current price.
- Unstable profitability: operating margin ranged from -5% to 28% over the last 7 years, with operating losses in 2 of them.
- Valued at a premium to its Diagnostics & Research peers: P/FCF 34.2x vs. a median of 24.1x and EV/EBITDA 22.1x vs. a median of 15.5x.
- Earnings are projected to decline (-9.8% per year).
Key Financial Data